Compare Inovio Pharmaceuticals Inc (INO) vs Realty Income Corp (O) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Realty Income Corp — how do they compare? Inovio Pharmaceuticals Inc trades at $0.74 (market cap $78.55M), while Realty Income Corp trades at $62.64 (market cap $58.56B). The key difference: Realty Income Corp is far larger — about 745.5× Inovio Pharmaceuticals Inc's market cap, and Realty Income Corp pays a 5.25% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| INO | O | |
|---|---|---|
Market Cap | $78.55M | $58.56B |
Sector | Health | Real Estate |
52-Week High | $2.87 | $67.56 |
52-Week Low | $0.66 | $55.93 |
Enterprise Value | $49.56M | $89.19B |
Dividend Yield | — | 5.25% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $0.772, up 4.83% in the last 24 hours, but technical indicators signal a bearish trend. The company shows minimal revenue of $65,340 in 2025 with a net loss of $84.95 million, though it has beaten EPS estimates in recent quarters. Key developments include an upcoming Q2 2026 earnings report on August 12, 2026, and a pending FDA decision on INO-3107 by October 30, 2026.
The outlook hinges on FDA approval of INO-3107, with a consensus price target of $3.25 implying significant upside. However, high cash burn, negative margins, and legal scrutiny pose substantial risks. Investors should weigh the binary event against persistent financial challenges.
Realty Income (O) trades at $62.36, up 0.76% with bearish technical signals despite recent earnings misses. The REIT maintains strong fundamentals with $5.75B revenue, 21.23% net margins, and consistent dividend payments. Recent $875M convertible notes offering signals growth ambitions while technical indicators show oversold conditions with RSI at 23.55.
Outlook remains balanced with analyst consensus at $67.29 target (8% upside) despite recent earnings disappointments. Key opportunities include dividend reliability (673 consecutive payments) and data center expansion, while risks involve rising debt levels (39.93% debt-to-asset) and interest rate sensitivity. The stock offers income stability with moderate growth potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Realty Income Corp
Realty Income owns roughly 11,400 properties, most of which are freestanding, single-tenant, triple-net-leased retail properties. Its properties are located in 49 states and Puerto Rico and are leased to 250 tenants from 47 industries. Recent acquisitions have added industrial, office, manufacturing, and distribution properties, which make up roughly 17% of revenue.
Read more on O →
